NOV03 meets primary, secondary endpoints in phase 3 trial

NOV03 met the primary and secondary endpoints in its first phase 3 trial, according to a press release from Bausch + Lomb and Novaliq.
NOV03 (perfluorohexyloctane) is being evaluated to treat dry eye disease signs and symptoms associated with meibomian gland dysfunction.
The multicenter, randomized, double-masked, saline-controlled GOBI trial enrolled 597 patients who were randomly assigned to receive NOV03 or saline solution placebo four times daily.
The eye drop met both primary co-endpoints, including a change from baseline in total corneal fluorescein staining with results through day 57

Full Story →